DIOPTICON A LIQ 0.3 %
PHENIRAMINE MALEATE : 0.3 % NAPHAZOLINE HYDROCHLORIDE : 0.025 % · DIN 02026465 · PHARMA STULLN INC.
Health Canada status: DORMANT
What is DIOPTICON A LIQ?
DIOPTICON A LIQ 0.3 % contains PHENIRAMINE MALEATE : 0.3 % NAPHAZOLINE HYDROCHLORIDE : 0.025 %. It is listed in the Health Canada Drug Product Database under DIN 02026465, held by PHARMA STULLN INC., supplied as SOLUTION for OPHTHALMIC administration. Health Canada currently lists it as dormant, status dated 14-Jan-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02026465 |
|---|---|
| Brand name | DIOPTICON A LIQ |
| Generic / active ingredient | PHENIRAMINE MALEATE : 0.3 % NAPHAZOLINE HYDROCHLORIDE : 0.025 % |
| Manufacturer | PHARMA STULLN INC. |
| Strength | 0.3 % |
| Dosage form | SOLUTION |
| Route of administration | OPHTHALMIC |
| Schedule | NON-PRESCRIPTION DRUGS |
| ATC code | S01GA51 NAPHAZOLINE, COMBINATIONS |
| AHFS class | 04:04.20 ; 52:32.00 |
| Biosimilar | No |
| Health Canada status | DORMANT |
| Status date | 14-Jan-2020 |
| Original market date | 1994-12-31 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code S01GA51 NAPHAZOLINE, COMBINATIONS. 5 of 21 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CLEAR EYES ALLERGY | 0.012 % | LIQUID | PRESTIGE BRANDS INC | MARKETED | DIN 02248059 |
| CLEAR EYES EXTRA STRENGTH REDNESS RELIEF | 0.50 % | SOLUTION | PRESTIGE BRANDS INC | MARKETED | DIN 02360837 |
| NAPHCON A | 0.025 % | SOLUTION | ALCON CANADA INC | MARKETED | DIN 00481408 |
| SOOTHE ALLERGY | 0.315 % | DROPS | BAUSCH & LOMB INC | MARKETED | DIN 00750794 |
| VISINE FOR ALLERGY WITH ANTIHISTAMINE | 0.025 % | DROPS | JOHNSON & JOHNSON INC | MARKETED | DIN 02242764 |
| ALBALON A | .5 % | LIQUID | ALLERGAN INC | CANCELLED POST MARKET | DIN 00433519 |
| ALLERGY EYE DROPS | 0.315 % | DROPS | BAUSCH & LOMB INC | CANCELLED POST MARKET | DIN 02394561 |
| BLUE COLLYRIUM | 0.2 MG | LIQUID | SANDOZ CANADA INCORPORATED | CANCELLED POST MARKET | DIN 02171937 |
| CLEAR EYES ACR BY MURINE | 0.1 MG | LIQUID | ABBOTT LABORATORIES, LIMITED | CANCELLED POST MARKET | DIN 02232454 |
| CLEAR EYES FOR DRY EYES PLUS REDNESS RELIEF | 0.012 % | SOLUTION | PRESTIGE BRANDS INC | CANCELLED POST MARKET | DIN 02294958 |
How can I get it?
This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.